Enzon Pharma (ENZN) Income Statement

Click line-items for a historical chart and %

Royalties	853K
Sale of in-process research and development
Contract research and development
Miscellaneous revenue	0
Total revenues	853K
Research and development – pipeline
Research and development – specialty and contracted services
General and administrative	146K
General and administrative – contracted services
Restructuring charge
Total operating expenses	200K
Operating (loss) income
Investment income, net
Interest expense
Other, net
Total other expense
(Loss) income from continuing operations, before income tax expense (benefit)
Income tax expense (benefit)	5.27M
(Loss) income from continuing operations
(Loss) income and gain from discontinued operations, net of income tax
Net (loss) income	-4.61M
Basic (in Dollars per share)
Diluted (in Dollars per share)
Basic (in Dollars per share)
Diluted (in Dollars per share)
Basic (in Dollars per share)	-0.1
Diluted (in Dollars per share)	-0.1
Weighted average shares – basic (in Shares)	-88.33M
Weighted average shares - diluted (in Shares)	-88.33M

Entities mentioned with ENZN

View All Entities